Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Psychiatry Reports
Published in: Current Psychiatry Reports 6/2017

Open Access 01-06-2017 | Complex Medical-Psychiatric Issues (MB Riba, Section Editor)

Depressive Spectrum Disorders in Cancer: Diagnostic Issues and Intervention. A Critical Review

Authors: Rosangela Caruso, Maria GiuliaNanni, Michelle B. Riba, Silvana Sabato, Luigi Grassi

Published in: Current Psychiatry Reports | Issue 6/2017

Login to get access

Abstract

Depressive spectrum disorders, including major depression, persistent depression, minor and sub-syndromal depression, and other forms of depressive conditions, such as demoralization, are among the most common psychiatric consequences of cancer patients, affecting up to 60% of patients. In spite of the negative effects and the burden for cancer patients and their families, these disorders often remain under-recognized and undertreated. The present review aims at summarizing the relevant data concerning the diagnostic challenges within the depressive spectrum disorders among cancer patients. Also, the most relevant data relative to integrated intervention, including psychopharmacological and psychosocial treatment, for depression in cancer patients are critically evaluated. It is mandatory that health care professionals working in oncology (e.g., oncologists, surgeons, radiation oncologists, primary care physicians, nurses, social workers, psychologists) receive training in the diagnosis and integrated management of the different types of disorder within the spectrum of clinical depression.
Literature
1.
2.
• Dauchy S, Dolbeault S, Reich M. Depression in cancer patients. European Journal of Cancer Suppl. 2013;11:205–15. This is a review of the most important aspects of depression in cancer, including pathogenesis and treatment.
3.
Mitchell AJ, Chan M, Bhatti H, Halton M, Grassi L, Johansen C, Meader N. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis. Lancet Oncol. 2011;12:160–74.CrossRefPubMed
4.
•• Caruso R, Nanni MG, Riba M, Sabato S, Mitchell A, Croce E, Grassi L. Depressive spectrum disorders in cancer: prevalence, risk factors and screening. A critical review Acta Oncologica. 2017;56:146–55. This is a very updated critical review of reviews and metanalyses related to the epidemiology of depression, the risk factors, and the screening and assessment methods for depressive spectrum disorders in cancer patients. CrossRefPubMed
5.
Grassi L, Berardi MA, Ruffilli F, Meggiolaro E, Andritsch E, Sirgo A, Caruso R, Juan Linares E, Bellé M, Massarenti S, Nanni MG; IOR-IRST Psycho-Oncology and UniFE Psychiatry Co-Authors.: Role of psychosocial variables on chemotherapy-induced nausea and vomiting and health-related quality of life among cancer patients: a European study Psychother Psychosom. 2015;84(6):339–47.
6.
• Sotelo JL, Musselman D, Nemeroff C. The biology of depression in cancer and the relationship between depression and cancer progression. Int Rev Psychiatry. 2014;26(1):16–30. This article describes and analyzes the most important pathways psychobiological relating depression with progression of cancer. CrossRefPubMed
7.
Grassi L, Nanni MG, Caruso R. Emotional distress in cancer: screening policy, clinical limitations, and educational needs. Journal of Medicine and the Person. 2010;8:51–9.
8.
Spoletini I, Gianni W, Repetto L, Bria P, Caltagirone C, Bossù P, Spalletta G. Depression and cancer: an unexplored and unresolved emergent issue in elderly patients. Crit Rev Oncol Hematol. 2008;65:143–55.CrossRefPubMed
9.
Greenberg DB. Barriers to the treatment of depression in cancer patients. J Natl Cancer Inst Monogr. 2004;32:127–35.CrossRef
10.
Mitchell AJ. Are one or two simple questions sufficient to detect depression in cancer and palliative care? A Bayesian meta-analysis. Br J Cancer. 2008;98:1934–43.CrossRefPubMedPubMedCentral
11.
Mitchell AJ, Meader N, Davies E, Clover K, Carter GL, Loscalzo MJ, Linden W, Grassi L, Johansen C, Carlson LE, Zabora J. Meta-analysis of screening and case finding tools for depression in cancer: evidence based recommendations for clinical practice on behalf of the Depression in Cancer Care consensus group. J Affect Disord. 2012;140(2):149–6.CrossRefPubMed
12.
13.
Cavanaugh SV. Depression in the medically ill. Critical issues in diagnostic assessment. Psychosomatics. 1995;36:48–59.CrossRef
14.
• Guan NC, Sulaiman AH, Zainal NZ, Boks MP, De Wit NJ. Diagnostic criteria for major depressive disorder in cancer patients: a review. Int J Psychiatry Med. 2013;45:73–82. This is an exploration of the different criteria for major depression in cancer, indicating that there is no standard reference test and precise definition of alternative criteria in literature studies and recognized diagnostic criteria for depression in cancer patients despite an apparent need for such criteria. CrossRefPubMed
15.
Akechi T, Ietsugu T, Sukigara M, Okamura H, Nakano T, Akizuki N, Okamura M, Shimizu K, Okuyama T, Furukawa TA, Uchitomi Y. Symptom indicator of severity of depression in cancer patients: a comparison of the DSM-IV criteria with alternative diagnostic criteria. Gen Hosp Psychiatry. 2009;31:225–32.CrossRefPubMed
16.
Mitchell AJ, Lord K, Symonds P. Which symptoms are indicative of DSMIV depression in cancer settings? An analysis of the diagnostic significance of somatic and non-somatic symptoms. J Affect Disord. 2012;138(1–2):137–48.CrossRefPubMed
17.
Reeve J, Lloyd-Williams M, Dowrick C. Revisiting depression in palliative care settings: the need to focus on clinical utility over validity. Palliat Med. 2008;22(4):383–91.CrossRefPubMed
18.
Wasteson E, Brenne E, Higginson IJ, Hotopf M, Lloyd-Williams M, Kaasa S. Loge JH; European Palliative Care Research Collaborative (EPCRC). Depression assessment and classification in palliative cancer patients: a systematic literature review. Palliat Med. 2009;23(8):739–53.CrossRefPubMed
19.
•• Lie HC, Hjermstad MJ, Fayers P, Finset A, Kaasa S, Loge JH. European Palliative Care Research Collaborative (EPCRC). Depression in advanced cancer--assessment challenges and associations with disease load. J Affect Disord. 2015;173:176–84. This is a large European study examining the effect of different scoring-methods of depressive symptoms on detecting depression, and the relationship between disease load and depression amongst patients with advanced cancer. CrossRefPubMed
20.
•• Zhao G, Okoro CA, Li J, White A, Dhingra S, Li C. Current depression among adult cancer survivors: findings from the 2010 Behavioral Risk Factor Surveillance System. Cancer Epidemiol. 2014;38(6):757–64. This is an important and large study of depression among cancer survivors, indicating the need for close monitoring of depressive symptoms even in patients recovered from cancer. CrossRefPubMed
21.
Rhebergen D, Graham R. The re-labelling of dysthymic disorder to persistent depressive disorder in DSM-5: old wine in new bottles? Curr Opin Psychiatry. 2014;27:27–31.CrossRefPubMed
22.
Wagner LI, Pugh SL, Small Jr W, Kirshner J, Sidhu K, Bury MJ, DeNittis AS, Alpert TE, Tran B, Bloom BF, Mai J, Yeh A, Sarma K, Becker M, James J, Bruner DW. Screening for depression in cancer patients receiving radiotherapy: feasibility and identification of effective tools in the NRG oncology RTOG 0841 trial. Cancer. 2017;123(3):485-93.
23.
•• Osório FL, Lima MP, Chagas MH. Screening tools for psychiatry disorders in cancer setting: caution when using. Psychiatry Res. 2015;229(3):739–4. This is a large study of 1384 patients who responded to several self-assessment instruments of whom 400 were interviewed by telephone to confirm the presence/absence of psychiatric diagnosis, with ROC analyses showing different levels of specificity and suggesting that sensitivity indicators should be used with caution in the cancer clinical setting. CrossRefPubMed
24.
Grassi L, Sabato S, Rossi E, Marmai L, Biancosino B. Affective syndromes and their screening in cancer patients with early and stable disease: Italian ICD-10 data and performance of the distress thermometer from the southern European psycho-oncology study (SEPOS). J Affect Disord. 2009;114(1–3):193-9.
25.
Casey P. Adult adjustment disorder: a review of its current diagnostic status. J Psychiatr Pract. 2001;7(1):32–40.CrossRefPubMed
26.
Casey P, Dowrick C, Wilkinson G. Adjustment disorders: fault line in the psychiatric glossary. Br J Psychiatry. 2001;179:479–81.CrossRefPubMed
27.
Baumeister H, Kufner K. It is time to adjust the adjustment disorder category. Curr Opin Psychiatry. 2009;22:409–12.CrossRefPubMed
28.
Baumeister H, Maercker A, Casey P. Adjustment disorder with depressed mood: a critique of its DSM-IV and ICD-10 conceptualisations and recommendations for the future. Psychopathology. 2009;42(3):139–47.CrossRefPubMed
29.
Israelashvili M. Should adjustment disorder be conceptualized as transitional disorder? In pursuit of adjustment disorders definition. J Ment Health. 2012;21(6):579–88.CrossRefPubMed
30.
31.
Grassi L, Mangelli L, Fava GA, Grandi S, Ottolini F, Porcelli P, Rafanelli C, Rigatelli M, Sonino N. Psychosomatic characterization of adjustment disorders in the medical setting: some suggestions for DSM-V. J Affect Disord. 2007;101(1–3):251–4.CrossRefPubMed
32.
Guidi J, Fava GA, Picardi A, Porcelli P, Bellomo A, Grandi S, Grassi L, Pasquini P, Quartesan R, Rafanelli C, Rigatelli M, Sonino N. Subtyping depression in the medically ill by cluster analysis. J Affect Disord. 2011;132(3):383–8.CrossRefPubMed
33.
Grassi L, Biancosino B, Marmai L, Rossi E, Sabato S. Psychological factors affecting oncology conditions. Adv Psychosom Med. 2007;28:57–71.CrossRefPubMed
34.
de Figueiredo JM. Depression and demoralization: phenomenologic differences and research perspectives. Compr Psychiatry. 1993;34(5):308–11.CrossRefPubMed
35.
Fava GA, Freyberger HJ, Bech P, Christodoulou G, Sensky T, Theorell T, Wise TN. Diagnostic criteria for use in psychosomatic research. Psychother Psychosom. 1995;63(1):1–8.CrossRefPubMed
36.
Clarke DM, Kissane DW. Demoralization: its phenomenology and importance. Australian and New Zealand Journal of Psychiatry. 2002;36(6):733–42.CrossRefPubMed
37.
Kissane DW, Clarke DM, Street AF. Demoralization syndrome—a relevant psychiatric diagnosis for palliative care. J Palliat Care. 2001;17(1):12–21.PubMed
38.
•• Fava GA, Cosci F, Sonino N. Current Psychosomatic Practice. Psychother Psychosom. 2017;86(1):13-30. This important paper presents and updates revising the criteria for the clusters of psychosocial dimensions, including demoralization, common in medecially ill patients and not detected by the ICD or DSM noslogy.
39.
Mangelli L, Fava GA, Grandi S, Grassi L, Ottolini F, Porcelli P, Rafanelli C, Rigatelli M, Sonino N. Assessing demoralization and depression in the setting of medical disease. J Clin Psychiatry. 2005;66(3):391–4.CrossRefPubMed
40.
Grassi L, Sabato S, Rossi E, Biancosino B, Marmai L. The use of the Diagnostic Criteria for Psychosomatic Research (DCPR) in oncology. Psychother Psychosom. 2005;74:100–7.CrossRefPubMed
41.
Clarke DM, Kissane DW, Trauer T, Smith GC. Demoralization, anhedonia and grief in patients with severe physical illness. World Psychiatry. 2005;4:96–105.PubMedPubMedCentral
42.
Grassi L, Rossi E, Sabato S, Cruciani G, Zambelli M. Diagnostic Criteria for Psychosomatic Research (DCPR) and psychosocial variables in breast cancer patients. Psychosomatics. 2004;45:483–91.CrossRefPubMed
43.
Vehling S, Mehnert A. Symptom burden, loss of dignity, and demoralization in patients with cancer: a mediation model. Psychooncology. 2014;23:283–90.CrossRefPubMed
44.
Fang CK, Chang MC, Chen PJ, Lin CC, Chen GS, Lin J, Hsieh RK, Chang YF, Chen HW, Wu CL, Lin KC, Chiu YJ, Li YC. A correlational study of suicidal ideation with psychological distress, depression, and demoralization in patients with cancer. Support Care Cancer. 2014;22:3165–74.CrossRefPubMedPubMedCentral
45.
• Tecuta L, Tomba E, Grandi S, Fava GA. Demoralization: a systematic review on its clinical characterization. Psychol Med. 2015;45:673–91. This is a comprehensive review of the instruments to assess the prevalence rates of demoralization, evidence of discriminant validity from major depression, factors associated with demoralization and evidence of clinical utility. CrossRefPubMed
46.
• Robinson S, Kissane DW, Brooker J, Burney S. A systematic review of the demoralization syndrome in individuals with progressive disease and cancer: a decade of research. J Pain Symptom Manag. 2015;49:595–610. This reviews summarizes the studies showing that demoralization is prevalent in patients with progressive disease or cancer (13–18%.) with a range of factors consistently associated with the syndrome, including poorly controlled physical symptoms, inadequately treated depression and anxiety, reduced social functioning, unemployment, and single status. CrossRef
47.
Tang PL, Wang HH, Chou FH. A systematic review and meta-analysis of demoralization and depression in patients with cancer. Psychosomatics. 2015;56(6):634–43.CrossRefPubMed
48.
Grassi L, Nanni MG. Demoralization syndrome: new insights in psychosocial cancer care. Cancer. 2016;122(14):2130–3.CrossRefPubMed
49.
• Caruso R, Grassi L, Nanni MG, Riba M. Psychopharmacology in psycho-oncology. Curr Psychiatry Rep. 2013;15(9):393. This is a review of studies examining the several medication types to be used in the treatment of psychiatric- and cancer-related symptoms stemming from the disease itself and/or its treatment, including sleep disturbance, loss of appetite, neuropathic pain, nausea, fatigue, and hot flashes. CrossRefPubMed
50.
•• Grassi L, Caruso R, Hammelef K, Nanni MG, Riba M. Efficacy and safety of pharmacotherapy in cancer-related psychiatric disorders across the trajectory of cancer care: a review. Int Rev Psychiatry. 2014;26(1):44–62. The review explores in a comprehensive way the several issues regarding the use of psychotropic drugs in cancer care, specifically pharmacokinetics and pharmacodynamics, interaction, safety, side effects, and efficacy in the integrated and multidimensional approach to cancer patients treated in different settings. CrossRefPubMed
51.
• Thekdi SM, Trinidad A, Roth A. Psychopharmacology in cancer. Curr Psychiatry Rep. 2015;17(1):529. This is a review of studies examining the several medications types to be used in the treatment of psychiatric and cancer-related symptoms. CrossRefPubMed
52.
•• Faller H, Schuler M, Richard M, Heckl U, Weis J, Küffner R. Effects of psycho-oncologic interventions on emotional distress and quality of life in adult patients with cancer: systematic review and meta-analysis. J Clin Oncol. 2013;31(6):782–93. This review and metanalysis analyzes the efficacy of the several forms of psychological intervention in cancer in 198 studies (covering 22,238 patients) reporting 218 treatment-control comparisons. The "duration of the intervention" had a moderator effect, with longer interventions producing more sustained effects. CrossRefPubMed
53.
Fisch M. Treatment of depression in cancer. J Natl Cancer Inst Monogr. 2004;32:105–11.CrossRef
54.
Rodin G, Lloyd N, Katz M, Green E, Mackay JA, Wong RK, Supportive Care Guidelines Group of Cancer Care Ontario Program in Evidence-Based Care. The treatment of depression in cancer patients: a systematic review. Support Care Cancer. 2007;15(2):123–36.CrossRefPubMed
55.
Williams S, Dale J. The effectiveness of treatment for depression/depressive symptoms in adults with cancer: a systematic review. Br J Cancer. 2006;94:372–90.CrossRefPubMedPubMedCentral
56.
Li M, Fitzgerald P, Rodin G. Evidence-based treatment of depression in patients with cancer. J Clin Oncol. 2012;30(11):1187–96.CrossRefPubMed
57.
Laoutidis ZG, Mathiak K. Antidepressants in the treatment of depression/depressive symptoms in cancer patients: a systematic review and meta-analysis. BMC Psychiatry. 2013;13:140.CrossRefPubMedPubMedCentral
58.
Riblet N, Larson R, Watts BV, Holtzheimer P. Reevaluating the role of antidepressants in cancer-related depression: a systematic review and meta-analysis. Gen Hosp Psychiatry. 2014;36(5):466–73.CrossRefPubMed
59.
• Ostuzzi G, Matcham F, Dauchy S, Barbui C, Hotopf M. Antidepressants for the treatment of depression in people with cancer. Cochrane Database Syst Rev. 2015;1(6):CD011006. General review of the randomized trials of the use of antidepressants in cancer care.
60.
Ostuzzi G, Benda L, Costa E, Barbui C. Efficacy and acceptability of antidepressants on the continuum of depressive experiences in patients with cancer: systematic review and meta-analysis. Cancer Treat Rev. 2015 Sep;41(8):714–24.CrossRefPubMed
61.
•• Sanjida S, Janda M, Kissane D, Shaw J, Pearson SA, DiSipio T, Couper J. A systematic review and meta-analysis of prescribing practices of antidepressants in cancer patients. Psychooncology. 2016;25(9):1002–16. The paper reviews the use of antidepressants in cancer patients, showing the considerable variation in the prescribing patterns of ADs and the lack of data regarding exact dose or follow-up regimens. CrossRefPubMed
62.
•• Walker J, Hansen CH, Martin P, Symeonides S, Ramessur R, Murray G, Sharpe M. Prevalence, associations, and adequacy of treatment of major depression in patients with cancer: a cross-sectional analysis of routinely collected clinical data. Lancet Psychiatry. 2014;1(5):343–50. This is a large 3-year study on 21,151 cancer patients who had participated in routine screening for depression in cancer clinics in Scotland, examining both the prevalence of major depression according to the different sites of cancer and the appropriateness of psychiatric treatment. CrossRefPubMed
63.
• Fisch MJ, Zhao F, Manola J, Miller AH, Pirl WF, Wagner LI. Patterns and predictors of antidepressant use in ambulatory cancer patients with common solid tumors. Psychooncology. 2015;24(5):523–32. This multi-institutional study enrolled 3106 ambulatory patients with cancer and showed that depressive symptoms were found in nearly half of patients, and one fourth of those with depressive symptoms were taking an antidepressant. CrossRefPubMed
64.
Jacob L, Kostev K, Kalder M. Treatment of depression in cancer and non-cancer patients in German neuropsychiatric practices. Psychooncology. 2016;25(11):1324–8.CrossRefPubMed
65.
Fisch MJ, Sherman LK, Adamus AT, Hung FC, Shen LF, Lange GO, Palmer JL. Trends in antidepressant prescribing at a comprehensive cancer center. J Clin Oncol. 2004;22(14suppl):6132.CrossRef
66.
Lal LS, Miller LA, Arbuckle R, Hung F, Feng C, Adamus A, Fisch MJ. Disparities in outpatient antidepressant prescribing patterns and determinants of resource utilization at a tertiary care cancer center. J Support Oncol. 2009;7(6):237–44.PubMed
67.
Pearson SA, Abrahamowicz M, Srasuebkul P, Buckley NA. Antidepressant therapy in cancer patients: initiation and factors associated with treatment. Pharmacoepidemiol Drug Saf. 2015;24(6):600–9.CrossRefPubMed
68.
Heron-Speirs HA, Harvey ST, Baken DM. Moderators of psycho-oncology therapy effectiveness: meta-analysis of therapy characteristics. J Psychosoc Oncol. 2013;31(6):617–41.CrossRefPubMed
69.
Zhang MF, Wen YS, Liu WY, Peng LF, Wu XD, Liu QW. Effectiveness of mindfulness-based therapy for reducing anxiety and depression in patients with cancer: a meta-analysis. Medicine (Baltimore). 2015;94(45):e0897.CrossRef
70.
Piet J, Würtzen H, Zachariae R. The effect of mindfulness-based therapy on symptoms of anxiety and depression in adult cancer patients and survivors: a systematic review and meta-analysis. J Consult Clin Psychol. 2012;80(6):1007–20.CrossRefPubMed
71.
Tamagawa R, Garland S, Vaska M, Carlson LE. Who benefits from psychosocial interventions in oncology? A systematic review of psychological moderators of treatment outcome. J Behav Med. 2012;35(6):658–73.CrossRefPubMed
72.
Galway K, Black A, Cantwell M, Cardwell CR, Mills M, Donnelly M. Psychosocial interventions to improve quality of life and emotional wellbeing for recently diagnosed cancer patients. Cochrane Database Syst Rev. 2012 Nov 14;11:CD007064. doi:10.​1002/​14651858.​CD007064.​pub2.PubMed
73.
74.
Gottlieb BH, Wachala ED. Cancer support groups: a critical review of empirical studies. Psychooncology. 2007;16:379–400.CrossRefPubMed
75.
Zimmermann T, Heinrichs N, Baucom DH. “Does one size fit all?” Moderators in psychosocial interventions for breast cancer patients: a meta- analysis. Ann Behav Med. 2007;34:225–39.CrossRefPubMed
76.
Manne SL, Andrykowski MA. Are psychological interventions effective and accepted by cancer patients? II. Using empirically supported therapy guidelines to decide. Ann Behav Med. 2006;32(2):98–103.CrossRefPubMed
77.
Andrykowski MA, Manne SL. Are psychological interventions effective and accepted by cancer patients? I. Standards and levels of evidence. Ann Behav Med. 2006;32(2):93–7.CrossRefPubMed
78.
Coyne JC, Lepore SJ, Palmer SC. Efficacy of psychosocial interventions in cancer care: evidence is weaker than it first looks. Ann Behav Med. 2006;32:104–10.CrossRefPubMed
79.
Newell SA, Sanson-Fisher RW, Savolainen NJ. Systematic review of psychological therapies for cancer patients: overview and recommendations for future research. J Natl Cancer Inst. 2002;94:558–84.CrossRefPubMed
80.
Osborn RL, Demoncada AC, Feuerstein M. Psychosocial interventions for depression, anxiety, and quality of life in cancer survivors: metanalyses. Int J Psychiatry Med. 2006;36:13–34.CrossRefPubMed
81.
Sheard T, Maguire P. The effect of psychological interventions on anxiety and depression in cancer patients: results of two meta-analyses. Br J Cancer. 1999;80:1770–80.CrossRefPubMedPubMedCentral
82.
Linden W, Girgis A. Psychological treatment outcomes for cancer patients: what do meta-analyses tell us about distress reduction? Psychooncology. 2012;21(4):343–50.CrossRefPubMed
83.
•• Breitbart W, Rosenfeld B, Pessin H, Applebaum A, Kulikowski J, Lichtenthal WG. Meaning-centered group psychotherapy: an effective intervention for improving psychological well-being in patients with advanced cancer. J Clin Oncol. 2015;33(7):749-5. This is the first study showing the efficacy of meaning centered psychotherapy in cancer settings, as a specific intervention to reduce hopelessness and psychsocoial suffering in patients with advanced stages of illnesses.
84.
Chochinov HM, Kristjanson LJ, Breitbart W, McClement S, Hack TF, Hassard T, Harlos M. Effect of dignity therapy on distress and end-of-life experience in terminally ill patients: a randomised controlled trial. Lancet Oncol. 2011;12(8):753-62.
85.
Lo C, Hales S, Chiu A, Panday T, Malfitano C, Jung J, Rydall A, Li M, Nissim R, Zimmermann C, Rodin G. Managing Cancer And Living Meaningfully (CALM): randomised feasibility trial in patients with advanced cancer. BMJ Support Palliat Care. 2016 Jan 19. doi: 10.​1136/​bmjspcare-2015-000866.
86.
Twillman RK, Manetto C. Concurrent psychotherapy and pharmacotherapy in the treatment of depression and anxiety in cancer patients. Psychooncology. 1998;7(4):285–90.CrossRefPubMed
87.
Hart SL, Hoyt MA, Diefenbach M, Anderson DR, Kilbourn KM, Craft LL, Steel JL, Cuijpers P, Mohr DC, Berendsen M, Spring B, Stanton AL. Meta-analysis of efficacy of interventions for elevated depressive symptoms in adults diagnosed with cancer. J Natl Cancer Inst. 2012;104(13):990–1004.CrossRefPubMedPubMedCentral
88.
Strong V, Waters R, Hibberd C, Murray G, Wall L, Walker J, et al. Management of depression for people with cancer (SMaRT oncology 1): a randomised trial. Lancet. 2008;372:40–8.CrossRefPubMed
89.
Walker J, Sharpe M. Depression care for people with cancer: a collaborative care intervention. Gen Hosp Psychiatry. 2009;31:436–41.CrossRefPubMed
90.
Duarte A, Walker J, Walker S, Richardson G, Holm Hansen C, Martin P, et al. Cost-effectiveness of integrated collaborative care for comorbid major depression in patients with cancer. J Psychosom Res. 2015;79(6):465–70.CrossRefPubMedPubMedCentral
91.
•• Sharpe M, Walker J, Holm Hansen C, Martin P, Symeonides S, Gourley C, et al. Integrated collaborative care for comorbid major depression in patients with cancer (SMaRT Oncology-2): a multicentre randomised controlled effectiveness trial. Lancet. 2014;384(9948):1099–108. This extremely well-performed RCT suggests that a specific depression care as a manualised, multicomponent collaborative care treatment that is delivered systematically by a team of cancer nurses and psychiatrists in collaboration with primary care physicians is an effective treatment for major depression in patients with cancer, and it offers a model for the treatment of depression comorbid with other medical condition. CrossRefPubMed
92.
Walker J, Hansen CH, Martin P, Symeonides S, Gourley C, Wall L, Weller D, Murray G, Sharpe M, SMaRT (Symptom Management Research Trials) Oncology-3 Team. Integrated collaborative care for major depression comorbid with a poor prognosis cancer (SMaRT Oncology-3): a multicentre randomised controlled trial in patients with lung cancer. Lancet Oncol. 2014;15(10):1168–76.CrossRefPubMed
93.
• Li M, Kennedy EB, Byrne N, Gérin-Lajoie C, Katz MR, Keshavarz H, Sellick S, Green E. Management of depression in patients with cancer: a clinical practice guideline. J Oncol Pract. 2016;12(8):747-56. The report updates the Cancer Care Ontario Program in Evidence-Based Care guideline for the management of depression in adult patients with cancer by covering pharmacologic, psychological, and collaborative care interventions, with a focus on integrating practical management tools to assist clinicians in delivering appropriate treatments for depression in patients with cancer.
94.
• Li M, Kennedy EB, Byrne N, Gérin-Lajoie C, Katz MR, Keshavarz H, Sellick S, Green E. Systematic review and meta-analysis of collaborative care interventions for depression in patients with cancer. Psychooncology. 2016; doi:10.​1002/​pon.​4286. The review shows that collaborative care interventions have emerged as multidisciplinary care delivery models, resulting in more long-term depression remission.
95.
Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet. 2007 Sep 8;370(9590):851–8.CrossRefPubMed
96.
Howell D, Keshavarz H, Esplen MJ, Hack T, Hamel M, Howes J, et al. on behalf of the Cancer Journey Advisory Group of the Canadian Partnership Against Cancer. A Pan Canadian Practice Guideline: Screening, Assessment and Care of Psychosocial Distress (Depression, Anxiety) in Adults with Cancer, Toronto: Canadian Partnership Against Cancer (Cancer Journey Advisory Group) and the Canadian Association of Psychosocial Oncology, July 2015.
97.
Rayner L, Price A, Hotopf M, Higginson IJ. The development of evidence-based European guidelines on the management of depression in palliative cancer care. Eur J Cancer. 2011;47:702–12.CrossRefPubMed
98.
Butow P, Price MA, Shaw JM, Turner J, Clayton JM, Grimison P, et al. Clinical pathway for the screening, assessment and management of anxiety and depression in adult cancer patients: Australian guidelines. Psychooncology. 2015;24(9):987–1001.CrossRefPubMed
99.
Andersen BL, DeRubeis RJ, Berman BS, Gruman J, Champion VL, Massie MJ, et al. American Society of Clinical Oncology.: screening, assessment, and care of anxiety and depressive symptoms in adults with cancer: an American Society of Clinical Oncology guideline adaptation. J Clin Oncol. 2014;32(15):1605–19.CrossRefPubMedPubMedCentral
100.
Caruso R, Nanni MG, Riba MB, Sabato S, Grassi L. The burden of psychosocial morbidity related to cancer: patient and family issues. Int'l Rev Psychiatry. (in press)
101.
Rubin G, Berendsen A, Crawford SM, Dommett R, Earle C, Emery J, et al. The expanding role of primary care in cancer control. Lancet Oncol. 2015;16:1231–72.CrossRefPubMed
102.
Wein S, Sulkes A, Stemmer S. The oncologist’s role in managing depression, anxiety, and demoralization with advanced cancer. Cancer J. 2010;16:493–9.CrossRefPubMed
103.
Hewitt M, Rowland JH. Mental health service use among adult cancer survivors: analyses of the National Health Interview Survey. J Clin Oncol. 2002;20:4581–90.CrossRefPubMed
104.
Kadan-Lottick NS, Vanderwerker LC, Block SD, Zhang B, Prigerson HG. Psychiatric disorders and mental health service use in patients with advanced cancer: a report from the coping with cancer study. Cancer. 2005;104:2872–81.CrossRefPubMedPubMedCentral
105.
Keszte J, Danker H, Dietz A, Meister E, Pabst F, Guntinas-Lichius O, Oeken J, Singer S, Meyer A. Course of psychiatric comorbidity and utilization of mental health care after laryngeal cancer: a prospective cohort study. Eur Arch Otorhinolaryngol. 2017;274(3):1591-9.
106.
Kaul S, Avila JC, Mutambudzi M, Russell H, Kirchhoff AC, Schwartz CL. Mental distress and health care use among survivors of adolescent and young adult cancer: a cross-sectional analysis of the National Health Interview Survey. Cancer. 2017;123(5):869-78.
107.
Whitney RL, Bell JF, Bold RJ, Joseph JG. Mental health needs and service use in a national sample of adult cancer survivors in the USA: has psychosocial care improved? Psychooncology. 2015;24(1):80–8.CrossRefPubMed
108.
Grassi L, Watson M, IPOS Federation of Psycho-Oncology Societies’ co-authors. Psychosocial care in cancer: an overview of psychosocial programmes and national cancer plans of countries within the International Federation of Psycho-Oncology Societies. Psychooncology. 2012;21(10):1027–33.CrossRefPubMed
109.
•• Grassi L, Fujisawa D, Odyio P, Asuzu C, Ashley L, Bultz B, Travado L, Fielding R, IPOS Federation of Psycho-oncology Societies’ coauthors. Disparities in psychosocial cancer care: a report from the International Federation of Psycho-oncology Societies. Psychooncology. 2016;25(10):1127–13. This is a study examining the problems and obstacles in delivering psychosocial care for cancer patients in the countries worldwide in which a national psycho-oncology society had been established, confirming the disparities and inequalities of psychosocial intervention available in cancer settings. CrossRefPubMed
Metadata
Title
Depressive Spectrum Disorders in Cancer: Diagnostic Issues and Intervention. A Critical Review
Authors
Rosangela Caruso
Maria GiuliaNanni
Michelle B. Riba
Silvana Sabato
Luigi Grassi
Publication date
01-06-2017
Publisher
Springer US
Published in
Current Psychiatry Reports / Issue 6/2017
Print ISSN: 1523-3812
Electronic ISSN: 1535-1645
DOI
https://doi.org/10.1007/s11920-017-0785-7

Other articles of this Issue 6/2017

Current Psychiatry Reports 6/2017 Go to the issue

Sex and Gender Issues in Behavioral Health (CN Epperson, Section Editor)

Sex Differences in Obesity and Mental Health

Substance Use and Related Disorders (F Levin and E Dakwar, Section Editors)

Update on Barriers to Pharmacotherapy for Opioid Use Disorders

Sleep Disorders (P Gehrman, Section Editor)

Sleep in Children with Autism Spectrum Disorder

Child and Family Disaster Psychiatry (B Pfefferbaum, Section Editor)

Addressing the Needs of Children and Youth in the Context of War and Terrorism: the Technological Frontier

Eating Disorders (S Wonderlich and JM Lavender, Section Editors)

Men, Muscles, and Eating Disorders: an Overview of Traditional and Muscularity-Oriented Disordered Eating

Mood Disorders (MA Oquendo and MF Grunebaum, Section Editors)

Biomarkers of Suicide Attempt Behavior: Towards a Biological Model of Risk